A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.

Thomas PayneMatthew ApplebyEllen BuckleyLinda M A van GelderBenjamin Harvey MullishMatilde SassaniMark J DunningDena HernandezSonja W ScholzAlisdair McNeillVincenzo LibriSarah MollJulian R MarchesiRosie TaylorLi SuClaudia MazzàThomas M JenkinsThomas Foltynie Oliver Bandmann

Published in: Movement disorders : official journal of the Movement Disorder Society (2023)

High-dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease-modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

double blind
high dose
placebo controlled
open label
low dose
clinical trial
phase iii
phase ii
study protocol
systematic review